Suzetrigine vs VX-993

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Diabetic Peripheral Neuropathic Pain

Shared mechanism: Voltage-gated sodium channel NaV1.8 · full Diabetic Peripheral Neuropathic Pain pipeline

Suzetrigine · Journavx

Marketed by Vertex Pharmaceuticals

Phase 3 in Diabetic Peripheral Neuropathic Painsmall molecule
Partial signal

NCT05660538 · Phase 2 · completed

The trial randomized 194 participants to three suzetrigine doses or active-controlled pregabalin, using quadruple blinding and matched placebos; the primary endpoint was the clinical symptom measure of change in weekly average pain score. The reported within-group pain changes were similar across arms, but statistical significance for the between-group primary comparisons is not provided, so the result is unclear rather than definitively met.

Next expected readout: January 2027 · NCT06696443 (registry estimate)

Reported efficacy

Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Change From Baseline in the Weekly Average of Daily Pain Intensity on a Numeric Pain Rating Scale (NPRS) (Baseline, At Week 12): Pregabalin -2.09 units on a scale (95% CI -2.65--1.52) vs Suzetrigine (SUZ): Low Dose -2.18 units on a scale (95% CI -2.94--1.41) vs Suzetrigine (SUZ): Mid Dose -2.11 units on a scale (95% CI -2.67--1.55) vs Suzetrigine (SUZ): High Dose -2.26 units on a scale (95% CI -2.82--1.70) (unclear)

Result source: NCT05660538

VX-993

Developed by Vertex Pharmaceuticals

Phase 2 in Diabetic Peripheral Neuropathic Painsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT06619860 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Diabetic Peripheral Neuropathic Pain

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSuzetrigineVX-993
Average daily pain, change-2.2 vs -2.1vs PregabalinLow Dose · wk 12 · n 24NCT05660538
2 other results
  • -2.1 vs -2.1 Mid Dose · wk 12 · n 48 · Phase 2 · primary NCT05660538
  • -2.3 vs -2.1 High Dose · wk 12 · n 48 · Phase 2 · primary NCT05660538
—Not reported
30% pain reduction70.8% vs 44.9%vs PregabalinLow Dose · wk 12 · n 24NCT05660538
2 other results
  • 46% vs 44.9% Mid Dose · wk 12 · n 50 · Phase 2 · secondary NCT05660538
  • 48% vs 44.9% High Dose · wk 12 · n 50 · Phase 2 · secondary NCT05660538
—Not reported
50% pain reduction41.7% vs 22.4%vs PregabalinLow Dose · wk 12 · n 24NCT05660538
2 other results
  • 32% vs 22.4% Mid Dose · wk 12 · n 50 · Phase 2 · secondary NCT05660538
  • 34% vs 22.4% High Dose · wk 12 · n 50 · Phase 2 · secondary NCT05660538
—Not reported
Sleep interference, change-2.2 vs -2.4vs PregabalinLow Dose · wk 12 · n 24NCT05660538
2 other results
  • -2.4 vs -2.4 Mid Dose · wk 12 · n 49 · Phase 2 · secondary NCT05660538
  • -2.1 vs -2.4 High Dose · wk 12 · n 47 · Phase 2 · secondary NCT05660538
—Not reported

Average daily pain, change

Suzetrigine
-2.2 vs -2.1vs PregabalinLow Dose · wk 12 · n 24NCT05660538
2 other results
  • -2.1 vs -2.1 Mid Dose · wk 12 · n 48 · Phase 2 · primary NCT05660538
  • -2.3 vs -2.1 High Dose · wk 12 · n 48 · Phase 2 · primary NCT05660538
VX-993
—Not reported

30% pain reduction

Suzetrigine
70.8% vs 44.9%vs PregabalinLow Dose · wk 12 · n 24NCT05660538
2 other results
  • 46% vs 44.9% Mid Dose · wk 12 · n 50 · Phase 2 · secondary NCT05660538
  • 48% vs 44.9% High Dose · wk 12 · n 50 · Phase 2 · secondary NCT05660538
VX-993
—Not reported

50% pain reduction

Suzetrigine
41.7% vs 22.4%vs PregabalinLow Dose · wk 12 · n 24NCT05660538
2 other results
  • 32% vs 22.4% Mid Dose · wk 12 · n 50 · Phase 2 · secondary NCT05660538
  • 34% vs 22.4% High Dose · wk 12 · n 50 · Phase 2 · secondary NCT05660538
VX-993
—Not reported

Sleep interference, change

Suzetrigine
-2.2 vs -2.4vs PregabalinLow Dose · wk 12 · n 24NCT05660538
2 other results
  • -2.4 vs -2.4 Mid Dose · wk 12 · n 49 · Phase 2 · secondary NCT05660538
  • -2.1 vs -2.4 High Dose · wk 12 · n 47 · Phase 2 · secondary NCT05660538
VX-993
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VX-993: no structured comparison results are available for Diabetic Peripheral Neuropathic Pain.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Suzetrigine: 4 of 4 rows · VX-993: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSuzetrigine
Dropout rate
16.1%High Dosea
NCT05660538 · Phase 2
show 2 more results
14.3%Low Dose
NCT05660538 · Phase 2
16.4%Mid Dose
NCT05660538 · Phase 2
Discontinued due to AEs
0%High Dosea
NCT05660538 · Phase 2
show 2 more results
0%Low Dose
NCT05660538 · Phase 2
1.8%Mid Dose
NCT05660538 · Phase 2
Serious AEs
1.8%High Dosea
NCT05660538 · Phase 2
show 2 more results
0%Low Dose
NCT05660538 · Phase 2
3.6%Mid Dose
NCT05660538 · Phase 2
Most frequent reported AEs
High Dosea
creatinine renal clearance decreased 10.9%
headache 1.8%
back pain 0%
NCT05660538 · Phase 2
show 2 more results
Low Dose
back pain 10.7%
oedema peripheral 3.6%
creatinine renal clearance decreased 0%
NCT05660538 · Phase 2
Mid Dose
headache 5.5%
creatinine renal clearance decreased 1.8%
dizziness 1.8%
NCT05660538 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Suzetrigine

Pain NRS -2.18 vs -2.09 Pregabalin score @ 12wkLow Dose
absolute change · score
NCT05660538 · Phase 2
show 2 more results
-2.11 vs -2.09 Pregabalin score @ 12wkMid Dose
NCT05660538 · Phase 2
-2.26 vs -2.09 Pregabalin score @ 12wkHigh Dose
NCT05660538 · Phase 2
Sleep Interference -2.2 vs -2.42 Pregabalin score @ 12wkLow Dose
absolute change · score
NCT05660538 · Phase 2
show 2 more results
-2.44 vs -2.42 Pregabalin score @ 12wkMid Dose
NCT05660538 · Phase 2
-2.15 vs -2.42 Pregabalin score @ 12wkHigh Dose
NCT05660538 · Phase 2
Pain 30 70.8% (n=24) vs 44.9% (n=49) Pregabalin @ 12wkLow Dose
responder rate · % of participants
NCT05660538 · Phase 2
show 2 more results
46% (n=50) vs 44.9% (n=49) Pregabalin @ 12wkMid Dose
NCT05660538 · Phase 2
48% (n=50) vs 44.9% (n=49) Pregabalin @ 12wkHigh Dose
NCT05660538 · Phase 2
Pain 50 41.7% (n=24) vs 22.4% (n=49) Pregabalin @ 12wkLow Dose
responder rate · % of participants
NCT05660538 · Phase 2
show 2 more results
32% (n=50) vs 22.4% (n=49) Pregabalin @ 12wkMid Dose
NCT05660538 · Phase 2
34% (n=50) vs 22.4% (n=49) Pregabalin @ 12wkHigh Dose
NCT05660538 · Phase 2
Pain NRS 70 8.3% (n=24) vs 10.2% (n=49) Pregabalin @ 12wkLow Dose
responder rate · % of participants
NCT05660538 · Phase 2
show 2 more results
22% (n=50) vs 10.2% (n=49) Pregabalin @ 12wkMid Dose
NCT05660538 · Phase 2
22% (n=50) vs 10.2% (n=49) Pregabalin @ 12wkHigh Dose
NCT05660538 · Phase 2
PGIC 1 2 50% (n=24) vs 46.9% (n=49) Pregabalin @ 12wkLow Dose
responder rate · % of participants
NCT05660538 · Phase 2
show 2 more results
52% (n=50) vs 46.9% (n=49) Pregabalin @ 12wkMid Dose
NCT05660538 · Phase 2
50% (n=50) vs 46.9% (n=49) Pregabalin @ 12wkHigh Dose
NCT05660538 · Phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Suzetrigine's landscape · VX-993's landscape